Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a clinical-stage biotechnology company advancing a pipeline of oral small molecule degrader medicines based on targeted protein degradation (TPD). This news page aggregates company announcements, clinical updates, collaboration developments and capital markets activity related to Kymera’s work in immunological and other serious diseases.
Readers can follow detailed updates on KT-621, Kymera’s investigational first-in-class oral STAT6 degrader in Phase 2 clinical testing for Type 2 inflammatory diseases such as atopic dermatitis and asthma. News items include Phase 1b and Phase 2 trial progress, biomarker and clinical endpoint data, and regulatory milestones such as U.S. FDA Fast Track designation for moderate to severe atopic dermatitis. Coverage also extends to KT-579, an investigational oral IRF5 degrader for immune-mediated conditions, as it moves from preclinical work toward first-in-human studies.
In addition to internal programs, this feed highlights updates on Kymera’s partnered assets, including the IRAK4 degrader KT-485/SAR447971 in collaboration with Sanofi for immuno-inflammatory diseases and the oral CDK2 molecular glue degrader program with Gilead Sciences for potential use in breast cancer and other solid tumors. Investors can also find information on public offerings of common stock, shelf registration statements, and other corporate events disclosed through press releases and SEC filings.
By reviewing Kymera news on this page, users can track clinical trial milestones, regulatory interactions, collaboration announcements and financing transactions that shape the company’s development trajectory. For those researching KYMR stock or the evolution of targeted protein degradation in immunology and oncology, this consolidated news view provides ongoing context around Kymera’s pipeline and corporate strategy.
Kymera Therapeutics (NASDAQ: KYMR) announced that data from its KT-621 BroADen Phase 1b trial in moderate-to-severe atopic dermatitis will be presented as a late-breaking oral presentation at the American Academy of Dermatology (AAD) 2026 Annual Meeting.
The oral session is scheduled for March 28, 2026 at 9:24 AM MT in Bellco Theatre, Denver. Kymera will also host a booth (#3551) in the exhibit hall. A copy of the presentation will be posted in Kymera's Resource Library after the session.
Kymera Therapeutics (NASDAQ: KYMR) reported Q4 and full-year 2025 results, advanced multiple clinical programs, and strengthened its balance sheet. Key highlights include $1.6 billion in cash (runway into 2029), positive KT-621 Phase 1b atopic dermatitis data, FDA Fast Track for KT-621, initiation of KT-579 Phase 1 dosing, and ongoing KT-621 Phase 2b studies with data expected mid-2027 (AD) and late-2027 (asthma).
Kymera Therapeutics (NASDAQ: KYMR) will take part in multiple investor conferences and fireside chats in early March 2026, including TD Cowen (March 3), UBS Biotech Summit (March 9), Leerink (March 10), Jefferies Biotech on the Beach (March 11), and Barclays (March 12).
Live webcasts of each presentation will be available under News and Events in the Investors section of the company website, with replays archived after the events.
Kymera Therapeutics (NASDAQ: KYMR) will report fourth quarter and full year 2025 financial results on February 26, 2026 and will host a video conference call and webcast at 8:30 a.m. ET.
Investors can register to join the live video call or view the livestreamed webcast via the company website; a replay will be archived after the event.
Kymera Therapeutics (NASDAQ: KYMR) announced participation in two investor fireside chats in February 2026. The company will present at Guggenheim Emerging Outlook: Biotech Summit on Feb 11, 2026 at 9:00 a.m. ET and at Oppenheimer Virtual Healthcare Life Sciences on Feb 26, 2026 at 2:00 p.m. ET.
Live webcasts and archived replays will be available in the Investors section of the company website under “News and Events.”
Kymera Therapeutics (NASDAQ: KYMR) announced dosing of the first patient in the BREADTH Phase 2b trial of KT-621, an oral STAT6 degrader for moderate to severe eosinophilic asthma. The randomized, double-blind, placebo-controlled study will enroll ~264 adults across three dose arms over 12 weeks.
The company expects BREADTH data in late-2027 and parallel BROADEN2 atopic dermatitis data by mid-2027, aiming to inform dose selection for subsequent Phase 3 registrational studies.
Kymera Therapeutics (NASDAQ: KYMR) outlined 2026 objectives to advance its oral immunology portfolio, highlighting clinical and preclinical milestones for STAT6 degrader KT-621 and IRF5 degrader KT-579.
Key points: KT-621 BROADEN2 Phase 2b in atopic dermatitis (enrollment complete in 2026; data mid-2027), BREADTH Phase 2b in eosinophilic asthma initiated (data late-2027), and FDA Fast Track in AD (Dec 2025). KT-579 Phase 1 healthy volunteer trial to start in 1Q26 with data in 2H26. Company reports $1.6 billion cash runway into 2029 and plans to advance at least one new development candidate toward IND in 2026.
Kymera Therapeutics (NASDAQ: KYMR) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 at 9:00 a.m. PT / 12:00 p.m. ET. Nello Mainolfi, PhD, Founder, President and CEO, will review Kymera’s clinical progress and anticipated 2026 milestones.
A live webcast of the presentation and Q&A will be available under “News and Events” in the Investors section of the company website at www.kymeratx.com, with a replay and archived presentation available after the event.
Kymera Therapeutics (NASDAQ: KYMR) closed an upsized underwritten public offering on Dec 11, 2025, selling 8,050,000 shares of common stock at a public offering price of $86.00 per share, which included 1,050,000 shares from the full exercise of the underwriters’ option.
The press release reports gross proceeds of approximately $692.3 million before deducting underwriting discounts, commissions and estimated offering expenses. The offering was conducted under an automatically effective Form S-3 registration and a final prospectus supplement filed with the SEC.
Kymera Therapeutics (NASDAQ: KYMR) announced that the U.S. FDA granted Fast Track designation to KT-621, a first-in-class oral STAT6 degrader for moderate to severe atopic dermatitis (AD), on December 11, 2025.
Fast Track follows positive BroADen Phase 1b AD results showing STAT6 degradation, biomarker modulation, clinical activity and supportive safety. The KT-621 BROADEN2 Phase 2b AD trial is ongoing with data expected by mid-2027, and the BREADTH Phase 2b asthma trial is planned to start in 1Q 2026. The company intends these studies to enable dose selection for parallel Phase 3 registration studies across Type 2 indications.